Semaglutide linked to sight-threatening eye condition, study results suggest
Researchers used data from nearly 17,000 patients to examine whether semaglutide prescriptions were associated with increased risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes mellitus, obesity, or who were overweight.
To their knowledge, the authors say their study is the first to report a link between semaglutide and NAION
Shutterstock.com
Semaglutide, a glucagon-like peptide-1 receptor agonist, may be associated with increased risk of a rare eye condition, results from a large-scale retrospective study have suggested.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
